[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335753-105":59,"doc-detail-335753-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","zymogen-granule-protein-16b-zg16b-is-a-druggable-epigenetic-target-to-modulate-the-mammary-extracellular-matrix","Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix","","High tissue density of the mammary gland supports tumorigenesis, motivating suppression of signals that drive matrix buildup. In non-malignant mammary epithelial cells, bexarotene and carvedilol suppress ZG16B via ARID1A interaction with a proximal enhancer, reducing ZG16B in vivo in normal breast tissue and MDA-MB231 xenografts. Secreted recombinant ZG16B promotes proliferation, motility, and clonogenic growth, shifting laminin, collagen, and integrin expression toward denser cell-matrix interactions. ZG16B also drives PI3K/Akt-dependent migration in breast cancer cells, while bexarotene plus carvedilol antagonizes ZG16B expression, glucose uptake, and tumor growth.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/zymogen-granule-protein-16b-zg16b-is-a-druggable-epigenetic-target-to-modulate-the-mammary-extracellular-matrix/335753/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/zymogen-granule-protein-16b-zg16b-is-a-druggable-epigenetic-target-to-modulate-the-mammary-extracellular-matrix/335753.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do bexarotene and carvedilol affect ZG16B in mammary epithelial cells?","Question",{"text":112,"@type":113},"In non-malignant mammary epithelial cells, bexarotene combined with carvedilol suppresses ZG16B through an interaction of ARID1A with a proximal enhancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What biological effects does recombinant ZG16B have in immortalized mammary epithelial cells?",{"text":117,"@type":113},"Secreted recombinant ZG16B stimulates mitogenic kinase phosphorylation, detachment, mesenchymal characteristics, and increases proliferation, motility, and clonogenic growth, accompanied by changes in matrix-related protein isoforms.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ZG16B influence breast cancer cell behavior compared with bexarotene plus carvedilol?",{"text":121,"@type":113},"ZG16B induces colony formation and anchorage-independent growth and promotes PI3K/Akt-dependent migration; in contrast, bexarotene plus carvedilol inhibits colony formation and reduces ZG16B expression, Ki67 levels, and glucose uptake in MDA-MB231 xenografts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335753,1790153430,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1111/cas.16382  \nOR I G I NAL ART I C L E  \nZymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix  \nMáté Lengyel1,2 | Ádám Molnár1 | Tamás Nagy3 | Sham Jdeed1,2 | Ildikó Garai3 | Zsolt Horváth4 | Iván P. Uray1,2,5   \n1Department of Clinical Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary  \n2The Molecular Cell and Immune Biology Doctoral School, University of Debrecen, Debrecen, Hungary  \n3 Department of Nuclear Medicine, University of Debrecen, Debrecen, Hungary  \n4Center of Oncoradiology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary  \n5Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen, Hungary  \nCorrespondence  \nIván P. Uray, Department of Clinical Oncology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary.  \nEmail: [uray.ivan@med.unideb.hu](uray.ivan@med.unideb.hu)  \nFunding information  \nNational Excellence program of the Ministry for Innovation and Technology, Hungary, Grant/Award Number: ÚNKP- 21-3; National Research, Development and Innovation Office of Hungary, Grant/ Award Number: K129218; European Social Fund, Grant/Award Number:  \nGINOP 2.3.2-15 2016-00020; University of Debrecen Scientific Research Bridging Funds (DETKA and ÁOK), Grant/Award Number: DE 37-11/2024  \nAbstract  \nHigh tissue density of the mammary gland is considered a pro-tumorigenic factor, hence suppressing the stimuli that induce matrix buildup carries the potential for cancer interception. We found that in non-malignant mammary epithelial cells the combination of the chemopreventive agents bexarotene (Bex) and carvedilol (Carv) suppresses the zymogen granule protein 16B (ZG16B, PAUF) through an interaction of ARID1A with a proximal enhancer. Bex +Carv also reduced ZG16B levels in vivo in normal breast tissue and MDA-MB231 tumor xenografts. The relevance of ZG16Bis underscored by ongoing clinical trials targeting ZG16B in pancreatic cancers, but its role in breast cancer development is unclear. In immortalized mammary epithelial cells, secreted recombinant ZG16B stimulated mitogenic kinase phosphorylation, detachment and mesenchymal characteristics, and promoted proliferation, motility and clonogenic growth. Highly concerted induction of specific laminin, collagen and integrin isoforms indicated a shift in matrix properties toward increased density and cell-matrix interactions. Exogenous ZG16B alone blocked Bex +Carv-mediated control of cell growth and migration, and antagonized Bex +Carv-induced gene programs regulating cell adhesion and migration. In breast cancer cells ZG16B induced colony formation and anchorage-independent growth, and stimulated migration in a PI3K/ Akt-dependent manner. In contrast, Bex +Carv inhibited colony formation, reduced Ki67 levels, ZG16B expression and glucose uptake in MDA-MB231 xenografts. These data establish ZG16B as a druggable pro-tumorigenic target in breast cell transformation and suggest a key role of the matrisome network in rexinoid-dependent antitumor activity.  \nK E Y WO R D S  \nARID1A, ECM, rexinoid, ZG16B  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.  \n1 | INTRODUCTION  \nWhile over 15% of breast cancer cases develop without an addiction to either estrogen receptors or Her2 receptors, RXR-selective retinoids have a well documented ability to suppress receptornegative breast cancer formation in transgenic mouse models.1–3 We hypothesized that the rexinoid-dependent suppression of pro-tumorigenic factors in premalignant breast cells represents valid targets for cancer inte","cbCaid16vMUl8agF","https://ap.wps.com/l/cbCaid16vMUl8agF","pdf",9850671,14,"English","# Abstract\n## Introduction\n## Materials and Methods\n### Cell lines and cell culture","[{\"question\":\"How do bexarotene and carvedilol affect ZG16B in mammary epithelial cells?\",\"answer\":\"In non-malignant mammary epithelial cells, bexarotene combined with carvedilol suppresses ZG16B through an interaction of ARID1A with a proximal enhancer.\"},{\"question\":\"What biological effects does recombinant ZG16B have in immortalized mammary epithelial cells?\",\"answer\":\"Secreted recombinant ZG16B stimulates mitogenic kinase phosphorylation, detachment, mesenchymal characteristics, and increases proliferation, motility, and clonogenic growth, accompanied by changes in matrix-related protein isoforms.\"},{\"question\":\"How does ZG16B influence breast cancer cell behavior compared with bexarotene plus carvedilol?\",\"answer\":\"ZG16B induces colony formation and anchorage-independent growth and promotes PI3K/Akt-dependent migration; in contrast, bexarotene plus carvedilol inhibits colony formation and reduces ZG16B expression, Ki67 levels, and glucose uptake in MDA-MB231 xenografts.\"}]","Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix | PDF",1790012206,35]